Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Confavreux, C.
Right arrow Articles by Ducerf, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Confavreux, C.
Right arrow Articles by Ducerf, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 2003; 96: 317
© 2003 Association of Physicians

Correspondence

Danazol-induced hepatocellular carcinoma

C. Confavreux, P. Sève, C. Broussolle, P. Renaudier and C. Ducerf

Department of Internal Medicine Department of Haematology Department of Surgery, Hospices Civils de Lyon, Lyon, France e-mail: christiane.broussolle@chu-lyon.fr

The first 10% of the full text of this article appears below.

Sir,

Danazol, an inhibitor of pituitary gonadotropin with weak androgenic effects, is currently used in the treatment of endometriosis, hereditary angio-oedema, systemic lupus erythematosus, and idiopathic thrombocytopenic purpura (ITP). Its hepatological side-effects have been well documented. These include reversible elevations of serum aminotransferase values,1 cholestatic hepatitis,2 hepatic peliosis3 and hepatocellular adenomas.4 Only a few . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?